A Phase Ib/II, Open Label Study of Siremadlin Monotherapy and in Combination With Donor Lymphocyte Infusion as a Treatment for Patients With Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplantation Who Are in Complete Remission But at High Risk for Relapse
Latest Information Update: 17 Jan 2025
At a glance
- Drugs Siremadlin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
Most Recent Events
- 08 Mar 2024 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 05 Feb 2024 Status changed from recruiting to discontinued (Study has been stopped following to strategic decision from the Sponsor. Not based on anysafety findings or safety concerns with siremadlin).
- 23 Nov 2023 This trial has been completed in Germany, according to European Clinical Trials Database record. (End date: 2023-10-26)